Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- INSP +11.3% (guidance), PHG +9.8%, OIS +5.5%, RVTY +4.3%, L +3.9%, CNA +2.7%, RDY +2.1%
Other news:
- CGTX +17.7% (proof-of-concept Phase 2 SHINE trial demonstrates consistent improvement in cognitive outcomes with once-daily oral CT1812)
- LGVN +15.7% (presents study results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B in Mild Alzheimer's Disease at the Alzheimer's Association International Conference)
- AVXL +14.1% (reports results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference)
- GH +12.6% (Shield blood test approved by FDA as a primary screening option, clearing path for medicare reimbursement and a new era of colorectal cancer screening)
- PBI +9.1% (trades higher after hours on report logistics startup Stord is acquiring its e-commerce fulfillment services ops, according to TheInformation)
- NAMS +5% (to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial)
- ALEC +4.8% (presents baseline characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024)
- ABOS +4% (presents patient experience and biomarker data from Phase 1 INTERCEPT-AD Study)
- CAMT +2.9% (receipt of orders for over $25 million from a tier-1 manufacturer specializing in High Bandwidth Memory)
- AZN +2.1% (reports Calquence fixed-duration combo improved 1L CLL PFS)
- CGEN +1.7% (FDA clearance of IND for COM503 for the treatment of solid tumors)
- VTLE +1.3% (Northern Oil & Gas announces second joint acquisition with Vital Energy (VTLE) in the Delaware Basin) SSL +1.3% (conclusion of the decision of the Minister of Forestry, Fisheries and the Environment on Sasol's appeal related to its Clause 12A Application)
- TLRY +1.1% (Aphria RX GmbH has received a trading license)